Alfresa Holdings Corporation

Alfresa Holdings Corporation

14.00
USD
0.00
(0.00%)
1.37EPS
10.40P/E
2.49BMarket Cap
Feb 08Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
11,315.3
10,824.31
11,711.63
11,777.42
12,012.93
12,398.25
12,748.7
12,332.8
12,338.56
13,322.61
14,905.63
15,950.69
17,075.37
17,596.42
Basic EPS, GAAP
115.5
102.48
158.99
142.57
164.25
195.91
190.26
115.75
153.57
127.42
154.13
147.54
229.64
214.39
Free Cash Flow per Basic Share
-218.69
89.08
107.25
95.69
162.49
155.94
62.61
-186.15
93.33
-61.17
370.49
-78.05
55.24
- -
Dividend per Share
24
27.35
32.25
34
38
44.2
49
51
54.54
55.04
63.85
67.6
66.15
- -
Book Value per Share
1,379.04
1,576.06
1,691.63
1,810.66
2,006.52
2,083.02
2,237.88
2,313.65
2,330.34
2,411.88
2,566.5
2,650.26
2,791.99
2,816.22
Tangible Book Value per Share
1,336.64
1,528.45
1,622.62
1,746.97
1,950.51
1,989.83
2,154.64
2,231.28
2,237.4
2,323.63
2,477.82
2,587.2
2,719.75
2,734.21
Basic Weighted Avg Shares
221
224
220
217
217
213
212
212
210
202
192
186
182
179
Sales/Revenue/Turnover
2,504,574
2,421,105
2,576,360
2,551,919
2,602,925
2,640,529
2,698,555
2,610,521
2,585,643
2,696,069
2,858,500
2,961,051
3,104,064
3,157,062
Operating Margin (%)
1.4
1.21
1.76
1.3
1.6
1.7
1.77
1.07
1.13
1.12
1.35
1.29
1.17
1.04
Depreciation Expense
10,011
9,374
10,850
11,017
10,564
10,756
11,777
11,868
12,824
13,302
13,514
14,923
15,048
- -
Net Income, GAAP
25,566
22,922
34,975
30,893
35,589
41,724
40,273
24,501
32,182
25,786
29,558
27,389
41,746
38,465
Effective Tax Rate (%)
40.84
38.42
34.6
30.44
30.75
31.8
31.93
32.95
33.16
33.17
32.47
30.29
32.54
33.67
Profit Margin (%)
1.02
0.95
1.36
1.21
1.37
1.58
1.49
0.94
1.24
0.96
1.03
0.92
1.34
1.22
Working Capital
123,155
132,369
129,623
148,296
166,313
176,873
197,433
208,551
213,658
208,795
214,244
199,535
220,840
207,234
LT Debt
4,338
4,301
4,656
4,530
4,384
4,444
4,873
4,230
3,244
2,461
33,372
33,962
33,933
30,000
Total Equity
305,435
354,120
368,728
393,547
435,932
442,080
474,897
489,957
471,832
488,334
479,858
482,246
507,900
494,732
Return on Invested Capital (%)
6.6
5.26
7.82
5.83
6.74
6.68
6.8
3.77
3.94
4.09
5.09
5.07
4.51
4.12
Return on Capital (%)
8.47
6.83
9.41
7.93
8.43
9.37
8.66
5.02
6.62
5.33
5.89
5.33
7.9
7.39
Return on Common Equity (%)
8.68
6.97
9.73
8.14
8.61
9.53
8.81
5.09
6.7
5.37
6.11
5.7
8.44
7.84

Capital Structure

JPY

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
1,687
- -
- -
LT Borrowings
30,000
30,000
30,000
LT Finance Leases
3,933
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
182
175
175
Market Capitalization
342,280
332,329
391,026

Working Capital

JPY

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
1,159,314
1,165,950
1,188,195
Cash, Cash Equivalents & STI
193,066
192,067
198,679
Accounts Receivable, Net
682,707
698,712
690,996
Inventories
172,858
173,062
192,973
Total Current Liabilities
938,474
964,222
980,961
Payables & Accruals
- -
- -
- -
ST Debt
1,687
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.34%
0.78%
5.32%
Free Cash Flow
-168.2%
-255.32%
-169.3%
Net Income, GAAP
4.93%
14.24%
52.42%
Sales/Revenue/Turnover
1.92%
3.55%
4.83%
Total Cash Common Dividend
5.58%
2.32%
-4.18%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
722,365
733,990
805,969
698,727
2,961,051
2026
758,118
771,644
833,324
740,978
3,104,064
2027
788,960
793,800
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
23.71
51.55
62.6
9.15
147.54
2026
27.52
35.83
112.59
53.74
229.64
2027
13.85
32.86
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
67.6
2026
- -
- -
- -
- -
66.15
2027
- -
- -
- -
- -
- -

Company Description

CEO
Ryuji Arakawa
Full Time Employees
12,525
Sector
Distribution services
Industry
Medical distributors
Address
Ote Center Building Tokyo SA Japan 100-0004
IPO Date
Sep 29, 2003
Business
Alfresa Holdings Corporation, established on September 29, 2003 and headquartered at 1-1-3 Otemachi, Chiyoda-ku, Tokyo, Japan, manages subsidiaries engaged in the wholesaling, manufacturing, marketing, import/export of pharmaceuticals, diagnostic reagents, medical devices and equipment; it operates dispensing pharmacies and related businesses as Japan's leading ethical pharmaceuticals wholesaler with consolidated net sales exceeding ¥2.9 trillion in the fiscal year ended March 2025. The company operates through six primary business segments: ethical pharmaceuticals wholesaling, which delivers pharmaceuticals, diagnostic reagents, medical devices, materials and nutritional foods from 207 nationwide distribution centers to hospitals, clinics and dispensing pharmacies; self-medication products wholesaling, providing over-the-counter drugs, health foods and supplements to drugstores and pharmacies as a total healthcare merchandising wholesaler; manufacturing, producing active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents and medical devices at eight bases compliant with GMP and QMS standards, including contract manufacturing; dispensing pharmacy and related businesses, operating 177 community-based family pharmacies supporting prevention to terminal care with home healthcare enhancements; regenerative medicine-related business, encompassing cell material supply, specified cell-processed products and CMO/CDMO services; and overseas business, featuring joint ventures like REMEJE PHARMACEUTICALS in China and Alfresa Codupha Healthcare Vietnam for medical devices and reagents primarily in Asia. Alfresa Holdings maintains a nationwide network across Japan with subsidiaries including Alfresa Corporation, Shikoku Alfresa, TS Alfresa, Tohoku Alfresa and others; it targets healthcare providers, pharmacies, drugstores and patients while advancing Total Supply Chain Services integrating development, manufacturing, distribution, sales and post-marketing surveillance. Recent developments include a March 2025 memorandum of understanding with Minaris Regenerative Medicine for collaborative cell therapy development, manufacturing and distribution utilizing Alfresa's logistics; a June 2025 strategic partnership and capital investment with HekaBio to accelerate biopharma and MedTech commercialization in CNS and regenerative medicine across Japan and Asia-Pacific; a November 2025 basic business alliance with K Pharma including investment in bonds with share warrants to establish iPS cell-derived regenerative medicine supply chains for products like KP8011; a January 2025 capital alliance with Medley via share exchange to bolster digital transformation synergies in pharmacy electronic records; and the May 2024 opening of the Tsukuba Distribution Center, alongside the launch of the 25-27 Mid-term Management Plan targeting ¥3.33 trillion net sales by fiscal 2027 under Vision 2032.

Company News

  • Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight